Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Diabetes Obes Metab 25(1):5667 Rosenstock J, Wysham C, Frias JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
This is when you remember why you started and gain confidence for the journey ahead
Funding Sanofi US, Inc
No commitment
The out-of-pocket cost without insurance is listed as around $1200/month, so this is definitely something you want to investigate thoroughly and make sure your insurance will cover it
Both medications are highly effective when prescribed correctly and managed with proper oversight
US$ 28.07
US$ 24.85
US$ 25.56
US$ 20.75
